Narrative review discusses osimertinib use in EGFR-mutated NSCLC patients with TKI resistance
Osimertinib may help some lung cancer patients after resistance develops
This narrative review examines the use of osimertinib and other EGFR-TKIs in non-small cell lung cancer patients harboring EGFR mutations af…
A review suggests osimertinib could be an option for non-small cell lung cancer patients with EGFR mutations who develop resistance to earli…
Five medications including daptomycin and durvalumab show positive association with drug-induced eosinophilic pneumonia in database analysis.
15,000 Cases Found: Which Drugs Harm Your Lungs?
A retrospective pharmacovigilance investigation analyzed 15,374 cases in FAERS and Vigibase databases to identify drug-induced eosinophilic …
A massive data review reveals which medicines might silently damage your lungs.
Case Report Details Aumolertinib Rechallenge Following Osimertinib-Induced Interstitial Lung Disease in Lung Adenocarcinoma
Can lung cancer drugs be restarted after severe lung injury?
This case report describes a 73-year-old male with stage IV lung adenocarcinoma and EGFR exon 19 deletions who experienced interstitial lung…
Doctors successfully restarted a powerful lung cancer drug after a patient's lungs healed from a dangerous reaction to the first one.
First-line osimertinib shows high response rates in EGFR-mutated NSCLC with active brain metastases.
Untreated Brain Metastases Respond Well to Osimertinib
This single-arm phase II trial evaluated first-line osimertinib in 100 patients with EGFR-mutated non-small cell lung cancer, including thos…
Osimertinib, a lung cancer drug, effectively treats untreated brain metastases, with an 81.8% response rate for measurable brain spots in a …
Amivantamab-lazertinib shows OS benefit over osimertinib in Asian EGFR-mutant NSCLC subset
Combination therapy shows longer survival than standard drug in Asian lung cancer patients
In a subset analysis of an RCT of 629 Asian patients with untreated EGFR-mutant advanced NSCLC, amivantamab-lazertinib prolonged overall sur…
Asian lung cancer patients on a new two-drug combination therapy lived longer than those taking the standard single drug, with a 26% lower r…